

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/073969 A1

(51) International Patent Classification:

C07D 407/14 (2006.01) A61P 29/00 (2006.01)
C07D 413/14 (2006.01) A61P 35/00 (2006.01)
C07D 498/10 (2006.01) A61K 31/506 (2006.01)
A61P 1/00 (2006.01) A61K 31/422 (2006.01)
A61P 9/00 (2006.01) A61K 31/4192 (2006.01)
A61P 13/12 (2006.01) C07D 405/14 (2006.01)

(21) International Application Number:

PCT/EP2021/077381

(22) International Filing Date:

05 October 2021 (05.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2020/077968

06 October 2020 (06.10.2020) EP

(71) Applicant: **IDORSIA PHARMACEUTICALS LTD**
[CH/CH]; Hegenheimmattweg 91, 4123 Allschwil (CH).

(72) Inventors: **BOLLI, Martin**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimmattweg 91, 4123 Allschwil (CH). **GATFIELD, John**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimmattweg 91, 4123 Allschwil (CH). **GRISOSTOMI, Corinna**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimmattweg 91, 4123 Allschwil (CH). **REMEN, Lubos**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimmattweg 91, 4123 Allschwil (CH). **SAGER, Christoph**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimmattweg 91, 4123 Allschwil (CH). **ZUMBRUNN, Cornelia**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimmattweg 91, 4123 Allschwil (CH).

(74) Agent: **VELKER, Jörg**; Idorsia Pharmaceuticals Ltd, Hegenheimmattweg 91, 4123 Allschwil (CH).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES



(57) Abstract: The present invention relates to compounds of Formula (I), wherein Ar¹, A, B, and R¹ are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

WO 2022/073969 A1